Clinical Research

Early data for Ablynx molecule in psoriasis

Country
Belgium

Early clinical data for a therapeutic protein developed by Ablnyx NV to treat patients with psoriasis has demonstrated that the treatment is safe, with some evidence of a reduction in disease activity. The treatment targets the interleukin-17 (IL-17) pathway.

Enterome starts trial of microbiome drug

Country
France

Enterome SA has started a Phase 1 study of its lead small molecule drug directed at the gut microbiome. The candidate drug targets the FimH protein as a means of blocking inflammation in Crohn’s disease.

Remission reported for aggressive brain tumours

Country
United States

A 50-year old patient with recurrent cancer involving tumours in both the brain and spinal cord has been treated with a chimeric antigen receptor (CAR) T cell therapy targeting an antigen that is overexpressed in a majority of glioblastomas.

Noxxon to test aptamer drug with Keytruda

Country
Germany

Noxxon Pharma AG has become the latest company to reach an agreement with Merck & Co Inc to test a portfolio drug with Keytruda (pembrolizumab), the US company’s immune checkpoint inhibitor.

Patient with mutant KRAS successfully treated

Country
United States

A patient with KRAS mutant metastatic colorectal cancer has been successfully treated with an autologous T cell receptor therapy, suggesting there may be a path forward for tackling difficult solid tumours, according to Kite Pharma Inc.

Tagrisso superior to chemotherapy in lung cancer

Country
United Kingdom

AstraZeneca Plc said that its recently approved lung cancer drug Tagrisso (osimertinib) has achieved another milestone, showing superiority to chemotherapy in a Phase 3 trial of patients with mutated metastatic non-small cell lung cancer.

Lucentis combination fails at Phase 3

Country
United States

Two Phase 3 trials which were seeking to show the superiority of a new combination treatment for patients with age-related macular degeneration (AMD) compared with the use of the licenced drug Lucentis alone, have failed to show an added benefit.

ReNeuron reports positive data from stroke trial

Country
United Kingdom

ReNeuron Plc has reported positive data from a Phase 2 trial of its allogeneic cell therapy for patients disabled by a stroke and plans to apply to regulatory authorities in the US and Europe to begin a pivotal study that could lead to possible registration.

Novartis says CTL019 achieved remission in 82% of patients

Country
United States

Novartis said that its chimeric antigen receptor (CAR) T cell therapy, developed jointly with the University of Pennsylvania, achieved significant disease remission in paediatric and young adult patients with B cell acute lymphoblastic leukaemia.